Precise Immunodetection of PTEN Protein in Human Neoplasia

Overview

Journal Cold Spring Harb Perspect Med

Specialty General Medicine

Date 2019 Sep 11

PMID 31501265

Citations 9

Authors

Rafael Pulido

Janire Mingo

Ayman Gaafar

Caroline E Nunes-Xavier

Sandra Luna

Leire Torices

Javier C Angulo

Jose I Lopez

Affiliations

Soon will be listed here.

Abstract

PTEN is a major tumor-suppressor protein whose expression and biological activity are frequently diminished in sporadic or inherited cancers. gene deletion or loss-of-function mutations favor tumor cell growth and are commonly found in clinical practice. In addition, diminished PTEN protein expression is also frequently observed in tumor samples from cancer patients in the absence of gene alterations. This makes PTEN protein levels a potential biomarker parameter in clinical oncology, which can guide therapeutic decisions. The specific detection of PTEN protein can be achieved by using highly defined anti-PTEN monoclonal antibodies (mAbs), characterized with precision in terms of sensitivity for the detection technique, specificity for PTEN binding, and constraints of epitope recognition. This is especially relevant taking into consideration that PTEN is highly targeted by mutations and posttranslational modifications, and different PTEN protein isoforms exist. The precise characterization of anti-PTEN mAb reactivity is an important step in the validation of these reagents as diagnostic and prognostic tools in clinical oncology, including their routine use in analytical immunohistochemistry (IHC). Here, we review the current status on the use of well-defined anti-PTEN mAbs for PTEN immunodetection in the clinical context and discuss their potential usefulness and limitations for a more precise cancer diagnosis and patient benefit.

Citing Articles

Potentiation by Protein Synthesis Inducers of Translational Readthrough of Pathogenic Premature Termination Codons in PTEN Isoforms.

Torices L, Nunes-Xavier C, Pulido R Cancers (Basel). 2024; 16(16).

PMID: 39199607 PMC: 11352852. DOI: 10.3390/cancers16162836.

Phosphatase and Tensin Homolog (PTEN) Expression as a Surrogate Biomarker Correlated With the Depth of Invasion in Cutaneous Malignant Melanoma.

Sun Z, Arnouk H Cureus. 2023; 15(9):e45295.

PMID: 37846279 PMC: 10576944. DOI: 10.7759/cureus.45295.

Novel anti-PTEN C2 domain monoclonal antibodies to analyse the expression and function of PTEN isoform variants.

Torices L, Nunes-Xavier C, Lopez J, Pulido R PLoS One. 2023; 18(8):e0289369.

PMID: 37527256 PMC: 10393154. DOI: 10.1371/journal.pone.0289369.

Pan-cancer genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome.

Vidotto T, Melo C, Lautert-Dutra W, Chaves L, Reis R, Squire J Sci Rep. 2023; 13(1):5049.

PMID: 36977733 PMC: 10050165. DOI: 10.1038/s41598-023-31759-6.

Functional analysis of PTEN variants of unknown significance from PHTS patients unveils complex patterns of PTEN biological activity in disease.

Torices L, Mingo J, Rodriguez-Escudero I, Fernandez-Acero T, Luna S, Nunes-Xavier C Eur J Hum Genet. 2022; 31(5):568-577.

PMID: 36543932 PMC: 10172195. DOI: 10.1038/s41431-022-01265-w.

References

Al-Khouri A, Ma Y, Togo S, Williams S, Mustelin T . Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem. 2005; 280(42):35195-202. DOI: 10.1074/jbc.M503045200. View

Tapparel C, Reymond A, Girardet C, Guillou L, Lyle R, Lamon C . The TPTE gene family: cellular expression, subcellular localization and alternative splicing. Gene. 2003; 323:189-99. DOI: 10.1016/j.gene.2003.09.038. View

Wang Y, Qu X, Shen H, Wang K, Liu Q, Du J . Predictive and Prognostic Biomarkers for Patients Treated with Anti-EGFR Agents in Lung Cancer: A Systemic Review and Meta-Analysis. Asian Pac J Cancer Prev. 2015; 16(11):4759-68. DOI: 10.7314/apjcp.2015.16.11.4759. View

Chaux A, Albadine R, Schultz L, Hicks J, Carducci M, Argani P . Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas. Hum Pathol. 2013; 44(10):2323-30. DOI: 10.1016/j.humpath.2013.05.014. View

Feng J, Dang Y, Zhang W, Zhao X, Zhang C, Hou Z . PTEN arginine methylation by PRMT6 suppresses PI3K-AKT signaling and modulates pre-mRNA splicing. Proc Natl Acad Sci U S A. 2019; 116(14):6868-6877. PMC: 6452682. DOI: 10.1073/pnas.1811028116. View

Chaux A, Schultz L, Albadine R, Hicks J, Kim J, Allaf M . Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas. Hum Pathol. 2012; 43(12):2129-37. PMC: 4029100. DOI: 10.1016/j.humpath.2012.01.009. View

Bassi C, Stambolic V . PTEN, here, there, everywhere. Cell Death Differ. 2013; 20(12):1595-6. PMC: 3824593. DOI: 10.1038/cdd.2013.127. View

Bedolla R, Prihoda T, Kreisberg J, Malik S, Krishnegowda N, Troyer D . Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res. 2007; 13(13):3860-7. DOI: 10.1158/1078-0432.CCR-07-0091. View

Guedes L, Morais C, Fedor H, Hicks J, Gurel B, Melamed J . Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer. Arch Pathol Lab Med. 2018; 143(3):338-348. DOI: 10.5858/arpa.2018-0068-OA. View

10.

Correia N, Girio A, Antunes I, Martins L, Barata J . The multiple layers of non-genetic regulation of PTEN tumour suppressor activity. Eur J Cancer. 2013; 50(1):216-25. DOI: 10.1016/j.ejca.2013.08.017. View

11.

Nosaka R, Yamasaki F, Saito T, Takayasu T, Kolakshyapati M, Amatya V . Role for loss of nuclear PTEN in a harbinger of brain metastases. J Clin Neurosci. 2017; 44:148-154. DOI: 10.1016/j.jocn.2017.06.004. View

12.

Pulido R, Baker S, Barata J, Carracedo A, Cid V, Chin-Sang I . A unified nomenclature and amino acid numbering for human PTEN. Sci Signal. 2014; 7(332):pe15. PMC: 4367864. DOI: 10.1126/scisignal.2005560. View

13.

Tan H, Bao J, Zhou X . Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity. Sci Rep. 2015; 5:12566. PMC: 4515826. DOI: 10.1038/srep12566. View

14.

Razis E, Bobos M, Kotoula V, Eleftheraki A, Kalofonos H, Pavlakis K . Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat. 2011; 128(2):447-56. DOI: 10.1007/s10549-011-1572-5. View

15.

Jamaspishvili T, Berman D, Ross A, Scher H, De Marzo A, Squire J . Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018; 15(4):222-234. PMC: 7472658. DOI: 10.1038/nrurol.2018.9. View

16.

Georgescu M, Kirsch K, Akagi T, Shishido T, Hanafusa H . The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci U S A. 1999; 96(18):10182-7. PMC: 17863. DOI: 10.1073/pnas.96.18.10182. View

17.

Lee Y, Chen M, Lee J, Zhang J, Lin S, Fu T . Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Science. 2019; 364(6441). PMC: 7081834. DOI: 10.1126/science.aau0159. View

18.

Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo A, Chen Y . Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer. 2010; 116(23):5517-26. PMC: 3568488. DOI: 10.1002/cncr.25502. View

19.

Tran T, Brettingham-Moore K, Duong C, Mitchell C, Clemons N, Phillips W . Molecular changes in the phosphatidylinositide 3-kinase (PI3K) pathway are common in gastric cancer. J Surg Oncol. 2013; 108(2):113-20. DOI: 10.1002/jso.23357. View

20.

Kim H, Shin S, Beom S, Jung M, Choi Y, Son T . Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Oncotarget. 2016; 7(28):44608-44620. PMC: 5190122. DOI: 10.18632/oncotarget.10115. View